- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06217484
Investigation of Effects of Delayed Feedback on Non-motor Symptoms in Individuals With Parkinson's Disease
January 19, 2024 updated by: Ekaterina Dobryakova, Kessler Foundation
Learning deficits are frequent in individuals with Parkinson's Disease.
Clear feedback is integral because through feedback individuals know whether they should stick with an action that they have been doing (if the feedback is positive), or change their course of action (if the feedback is negative).
Learning though immediate feedback has been shown to be depended on the brain chemical dopamine that is disrupted in individuals with Parkinson's Disease.
During learning, feedback can also be presented after a delay.
The investigators propose that learning through delayed feedback will lead to greater learning in individuals with Parkinson's Disease, since learning through delayed feedback does not rely on dopamine.
During the proposed paradigm, participants with Parkinson's Disease complete a multiple-choice test.
After making their selection on the multiple-choice test, they either see feedback immediately or are given feedback 25 minute later after reviewing their selection on the multiple-choice test.
The investigators hypothesize that participants will learn better when they are provided with delayed feedback.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
40
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kai Sucich, MA
- Phone Number: 973-323-3693
- Email: ksucich@kesslerfoundation.org
Study Contact Backup
- Name: Ekaterina Dobryakova, PhD
- Email: edobryakova@kesslerfoundation.org
Study Locations
-
-
New Jersey
-
East Hanover, New Jersey, United States, 07936
- Recruiting
- Kessler Foundation
-
Contact:
- Kai Sucich, MA
- Phone Number: 973-323-3693
- Email: ksucich@kesslerfoundation.org
-
Contact:
- Ekaterina Dobryakova, PhD
- Email: edobryakova@kesslerfoundation.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Individuals with Parkinson Disease
Description
Inclusion Criteria:
- Only participants with scores above 24/30 on the Montreal Cognitive Assessment will be recruited for participation to exclude dementia.
Exclusion Criteria:
- Individuals with neurological conditions other than PD such as epilepsy, multiple sclerosis, brain tumors, etc. will be excluded to control for the effects these conditions have on the brain and behavior.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Parkinson Disease
Participants with Parkinson Disease; Single group.
|
participants learn through either immediate or delayed feedback during a computer task
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent correct responses will be collected through the computer software
Time Frame: testing lasts 60 minutes and completed in 1 day
|
Response accuracy per trial
|
testing lasts 60 minutes and completed in 1 day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ekaterina Dobryakova, PhD, Kessler Foundation
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2023
Primary Completion (Estimated)
September 1, 2025
Study Completion (Estimated)
December 31, 2025
Study Registration Dates
First Submitted
December 28, 2023
First Submitted That Met QC Criteria
January 19, 2024
First Posted (Actual)
January 22, 2024
Study Record Updates
Last Update Posted (Actual)
January 22, 2024
Last Update Submitted That Met QC Criteria
January 19, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- E-1228-23
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on delayed feedback
-
University of North Carolina, Chapel HillNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedAphasia | Cerebrovascular Accident | Apraxia of SpeechUnited States
-
MGH Institute of Health ProfessionsRecruitingDevelopmental Language DisorderUnited States
-
Iran University of Medical SciencesCompletedStuttering/ DevelopmentalIran, Islamic Republic of
-
Abby BraitmanNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Enrolling by invitationCollege Student DrinkingUnited States
-
Danish Breast Cancer Cooperative GroupRecruitingBreast Neoplasm Female | Breast Implant; Complications | Complication of Radiation TherapyDenmark
-
Duke UniversityUniversity of Pittsburgh; University of South Carolina; Whole Child InternationalCompletedMental Health Wellness 1 | Health Behavior | Child RearingEl Salvador
-
University of MichiganEnrolling by invitationDepression | Anxiety | Sleep Disturbance | AddictionUnited States
-
University of Rhode IslandBrown University; Women and Infants Hospital of Rhode IslandCompleted
-
University Hospital, CaenUnknown